2026 Legal Alert: Law Offices of Timothy L. Miles
As of March 2026, our firm is tracking two major corporate accountability trends: the surge in Fume Event Lawsuits involving Airbus “bleed air”and Zepbound and Vision Loss along with other GlP-1 Drugs. Whether it’s toxic cabin air or pharmaceutical negligence, we are providing the latest evidence for victims seeking justice.
Introduction to Zepbound and Vison Loss: Critical Patient Updates
The Zepbound and vision loss nighmare continues with attorneys fielding calls from patients taking Zepbound (tirzepatide) who have suffered serous Zepbound vision problems including the loss of vision in one eye from a detaiched retina. Serious vision healh concerns have skyrocked recently regarding potential Zepbound vision side effects, prompting individuals who took Zepbound and suffered vision loss to file a Zepbound vision loss lawsuit against the drug’s manufacturer, Eli Lilly and Company alleging that the company failed to warn patients or doctors about these very serious Zebpound eye side effects.
Specifically, there have been cases of a condition called nonarteritic anterior ischemic optic neuropathy (NAION) being reported among patients taking this medication. This has prompted further investigation into whether there is a link between tirzepatide and serious eye complications which current clinical trials and an abundance of adverse event reports by patients have confirmed.
In this critical Zepbound and vision loss update we will inform you on the status of the Zepbound vision loss lawsuit as well as address the numerous Zepbound vision prolems afflicting patients including, unfortunatley, permanent vision loss on one eye.
If you are a patient taking Zepbound, please read this carefully as this is a very serious and debilitating vison health issue that may Zepbound uses are completely unaware off and need to undestand the vital question:
Is the weight loss worth the loss of an eye.

Current Status of the National MDL (March 2026)
- Case Count: There are now 3,363 pending cases in the federal MDL, which is actually shrinking as meritless claims are purged.
- Vision Loss Branch: A separate track for NAION (vision loss) claims was finalized in December 2025 and is now moving forward alongside the gastrointestinal cases.
- Bellwether Selection: The court is currently selecting “test cases” (bellwethers) for early 2026 trials, which will finally put a real number on what these cases are worth.
The “Gold Standard” Diagnostic Tests
- Gastric Emptying Scintigraphy: The primary “gold standard” test where a patient’s digestion is tracked via a radio-labeled meal.
- Wireless Motility Capsule (SmartPill): A swallowed sensor that measures transit time throughout the entire GI tract.
- 13C-Spirulina Breath Test: A non-invasive alternative that measures CO2 levels to determine gastric emptying speed.
Insufficient Evidence (What to Avoid)
- You should be advissed that common scans like CT scans, MRIs, and endoscopies are generally insufficient for the MDL.
- While these can rule out physical obstructions, they do not measure the actual speed of stomach motility, which is the core requirement for a gastroparesis diagnosis.
- A dedicated “Vision Injury Track” was established in late 2025. This specifically addresses NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy), an “eye stroke” linked to GLP-1 drugs like Zepbound and Ozempic.
Zepbound and Blurry Vision vs. NAION Update
- The Trap: Most Zepbound users are told Zepbound and blurry vision is just a temporary side effect of blood sugar changes. This is simply not true in many instances. Instead, it is a warning sign of a much more serious Zepbound vision problem that can lead to devestating effects including permanant Zepbound blindness.
- The Legal Reality: New 2026 lawsuits (MDL No. 3163) argue that this “blurriness” can actually be an early sign of NAION(non-arteritic anterior ischemic optic neuropathy), also called an “eye stroke,” which leads to permanent blindness.
- Key Distinction: Temporary blurriness usually fluctuates; NAION typically presents as sudden, painless vision loss in one eye, often noticed right after waking up.

Symptoms of NAION
- Sudden, painless vision loss: Often noticed upon waking.
- Visual field defects: Typically, the upper or lower half of vision is lost (altitudinal defect).
- Decreased color vision
The American Academy of Ophthalmology states the following on the clinical features of NAION:
Symptoms. NAION typically presents as an acute, monocular, painless loss of vision. Although bilateral presentation is rare, it can occur in the setting of severe blood pressure fluctuation due to surgery, hemodialysis, or excessive blood loss. Ocular discomfort, headache, and periocular pain ]are not typical but have been reported in 10% of patients. Presence of pain should prompt investigation for alternative causes of the vision loss.
Signs. Visual loss is usually less severe in NAION than in arteritic anterior ischemic optic neuropathy (AAION). The absence of light perception is rare in NAION and, if present, should lead the clinician to suspect AAION. At presentation, 50% of NAION patients have VA better than 20/64, and 66% have better than 20/200. Some NAION patients may have normal VA.
The typical visual field defect in NAION is inferior altitudinal vision loss. However, other patterns may be detected, including inferior nasal loss or central, cecocentral, and/or arcuate scotomas.
As in other types of optic neuropathy, dyschromatopsia and relative afferent pupillary defect may be present in NAION. The degree of dyschromatopsia in NAION is proportionate to the VA loss, unlike in optic neuritis, in which the dyschromatopsia is much more severe than would be expected for the level of VA.
Causes and Risk Factors
- Anatomy: A “crowded” optic disc (small cup-to-disc ratio).
Diagnosis and Prognosis
- Diagnosis: Primarily based on clinical examination, showing optic disc swelling (edema).
- Prognosis: The initial vision loss is usually permanent. The optic disc swelling typically resolves in 1 to 2 months.
- Risk to second eye: There is a 15% risk of the second eye becoming involved within 5 years

Treatment and Management
- Controlling blood pressure (especially preventing nighttime dips).
- Managing diabetes and sleep apnea.
- Avoiding excessive hypotension (low blood pressure) during surgeries
Clinical Research Confirming a Higher Risk of NAION in Patients Taking Zepbound and other GLP-1 Drugs
What Occular Manifestations Zepbound and Other GLP-1 Can Cause
Clinical research and adverse event reporting by patients suggest strongly insinuates that GLP-1 drugs may cause:
- Restricted blood flow to the optic nerve
- Sudden optic nerve ischemia: A medical emergency causing rapid, usually permanent, painless vision loss in one or both eyes due to reduced blood flow (oxygen) to the optic nerve
- Posterior vitreous detachmentwhich can lead to a tear in the retina and detachment of the retina
- Retinal artery occlusion which is an, often permanent, sudden, painless loss of vision in one eye caused by a blockage in the retinal artery, acting as an ocular stroke
- Inflammation of ocular tissues, often termed uveitis or general ocular inflammatory disease, involves redness, pain, severe light sensitivity, and potential vision loss.
Key Findings on GLP-1s and NAION
- Study Data: One published study appearing in JAMA Ophthalmology on July 3, 2024, found a link between GLP-1 and an increased risk of NAION. The study found a higher risk of NAION in patients prescribed GLP-1 compared to those on non-GLP-1 RA medications.
- Risk Factors: One study found that individuals with diabetes using semaglutide were over 4 times more likely to be diagnosed with NAION, and those with obesity were over 7 times more likely to experience this condition. Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes, JAMA Ophthalmology (Aug. 11, 2025)
- Tirzepatide (Zepbound) Findings: While some studies focused on semaglutide, others included tirzepatide (Zepbound), with recent data indicating a potential association with NAION and other optic nerve issues.
- Inconsistent Evidence: Some studies, including a meta-analysis, did not find a strong correlation, indicating that more research is needed to establish a definitive, direct cause-and-effect relationship.
- Concerns for Users: Experts advise that patients experiencing sudden, painless vision loss, blurring, or shadowing should seek immediate medical attention.
- Recent Clinical Investigations: Have identified a concerning association between GLP-1 receptor agonists, including Zepbound (tirzepatide), and elevated rates of NAION.
- Zepbound NAION Lawsuit: A landmark study published in 2024 examined medical records from a large ophthalmology practice, revealing statistically significant increases in NAION incidence among patients prescribed these medications for type 2 diabetes and obesity management.
- Another study established a concerning connection between GLP-1 receptor agonists—including both Zepbound (tirzepatide) and Ozempic (semaglutide)—and increased incidence rates of NAION. Clinical observations have documented elevated occurrences of this condition among patients prescribed these medications compared to individuals using alternative diabetes treatments.

Clinical Research and Finding
- Retrospective Cohort Study (2024):
- Analyzed data from over 16,000 patients
- Found a higher incidence of NAION in patients using GLP-1 receptor agonists compared to those on other diabetes medications
- Reported a hazard ratio of 4.28 for patients with type 2 diabetes and 7.64 for patients with obesity
- Pharmacovigilance Analysis (2023):
- Examined adverse event reports submitted to regulatory agencies
- Identified a disproportionate number of vision-related events associated with GLP-1 receptor agonists
- Suggested a potential class effect rather than a drug-specific issue
- Prospective Observational Study (2024):
- Followed 5,000 patients newly prescribed Zepbound for 18 months
- Documented a small but statistically significant increase in the incidence of Zepbound vision problems compared to matched controls
- Noted that risk factors such as hypertension and pre-existing eye conditions may contribute to increased vulnerability to Zepbound vision side effects
- A large Danish registry study also found semaglutide use was associated with higher NAION risk over five years, while NAION remained uncommon overall.
- The European Medicines Agency (EMA), a regulatory body, estimates that NAION may affect up to about 1 in 10,000 people taking semaglutide (Ozempic and Wegovy).
Possible Mechanism
Researchers suggest that the rapid reduction of blood glucose levels caused by these drugs, or potential effects on vascular health, might contribute to rreduced blood flow to the optic nerve, resulting in NAION.
Zepbound and Eye Pain & Inflammation
- While not as common as blurriness, eye pain is being cited in some of the roughly 3,363 GLP-1 lawsuits active as of March 2026.
- Calls continue to come in with Zepbound eye-pain, blurry vision, floaters, and unfortunatley permanent loss of vision in one eye and a very painful condition, as opposed to diabetic retinopathy, which is usually painless.
Zepbound and Floaters and Retinal Issues
- Newer reports of floaters (spots or strings in vision) are being investigated as potential signs of retinal detachment or accelerated diabetic retinopathy complications.
- The current Eli Lilly Zepbound label mentions retinopathy but does not explicitly warn about the sudden onset of floaters leading to permanent damage.
Treatment and Management
Why might someone experience Zepbound and Sudden Blurry Vision?


